Inhibikase Therapeutics
IKT· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -36.9% in FY2025
Mark Iwicki is the CEO of Inhibikase Therapeutics and was paid $30.6M in FY2025 (Dec).
Pay$100 in the stock at the end of FY24 → $63
Executives4
See all- 1Mark IwickiChief Executive Officer and DirectorFY2025
- 2Chris Cabell, M.D.President and Head of Research and DevelopmentFY2025
- 3David McIntyreChief Financial OfficerFY2025
- 4Milton H. Werner, Ph.D.Former President and Chief Executive OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allInhibikase Therapeutics paid its 4 named executives $44.4M in total in FY2025 (Dec). CEO Mark Iwicki was paid $30.6M of that.
| Name | |||
|---|---|---|---|
| Mark IwickiChief Executive Officer and Director | Not disclosed | Not disclosed | |
| Chris Cabell, M.D.President and Head of Research and Development | Not disclosed | Not disclosed | |
| David McIntyreChief Financial Officer | Not disclosed | Not disclosed | |
| Milton H. Werner, Ph.D.Former President and Chief Executive Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Inhibikase Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Amit MunshiChair · 0 yr on the boardIndependentCompensation—Paid as an executive
- Dennis BermanDirector · 4 yr on the boardIndependentCompensation (Chair), Executive Officers—Paid as an executive
- Arvind KushDirector · 0 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- Roberto BelliniDirector · 0 yr on the boardIndependentCorporate Governance and Nominating (Chair), Executive Officers—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | May 12, 2025 | FY2024 |
| Annual report | 10-K | Mar 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 27, 2024 | FY2023 |
